By contrast, CheckMate 274 (double-blind; anti-PD-1 nivolumab) reported a DFS benefit in both the ITT and PD-L1–high cohorts; differences in blinding, PD-L1 assay/scoring (e.g., tumor-cell vs. immune-cell algorithms), population composition, and statistical hierarchy may underlie the discrepant readouts. Here, CD274 is linked to neoplasm.